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Abstract 24 
Bovine Parainfluenza Virus Type 3 (BPI3V) infections are often asymptomatic, causing respiratory 25 
tissue damage and immunosuppression, predisposing animals to severe bacterial pneumonia, the 26 
leading cause of Bovine Respiratory Disease (BRD) mortality.  As with many pathogens, routine 27 
BPI3V serology does not indicate the presence of damaged respiratory tissue or active infection.  In 28 
vitro proteomic marker screening using disease relevant cell models could help identify markers of 29 
infection and tissue damage that are also detectable during in vivo infections.  This study utilised a 30 
proteomic approach to investigate in vitro cellular responses during BPI3V infection to enhancing 31 
the current understanding of intracellular host-virus interactions and identify putative markers of in 32 
vivo infection. Through 2D gel electrophoresis proteomic analysis, BPI3V Phosphoprotein P and 33 
host T-complex Protein 1 subunit theta were found to be accumulated at the latter stages of 34 
infection within bovine fibroblasts. These proteins were subsequently detected using targeted 35 
multiple reaction monitoring (MRM) mass spectrometry in the plasma of animals challenged with 36 
BPI3V, with differential protein levels profile observed dependant on animal vaccination status.  37 
Potential mechanisms by which BPI3V overcomes host cellular immune response mechanisms 38 
allowing for replication and production of viral proteins were also revealed.  Assessment of 39 
circulating protein marker levels identified through an in vitro approach as described may enable 40 
more effective diagnosis of active viral infection and diseased / damaged respiratory tissue in 41 
animals and allow for more effective utilisation of preventative therapeutic interventions prior to 42 
bacterial disease onset and significantly aid the management and control of BRD.   43 
 44 
  45 
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Introduction 46 
Bovine Respiratory Disease (BRD) is a multifactorial disease characteristic of a viral-bacterial 47 
synergistic infection with predisposition from environmental stressors.  The disease constitutes a 48 
major source of economic loss through mortality, clinical disease and associated treatments with 49 
long lasting reduced growth performance of infected young stock (Griffin, 1997).  Bovine 50 
Parainfluenza Virus-3 (BPI3V) is one of the major viral pathogens of the BRD complex (Kahrs, 51 
2001).  BPI3V induced respiratory tract damage, resulting from the destruction of the ciliated 52 
respiratory epithelium (Bryson, 1985) and immunosuppression via depression of local cellular 53 
immunity by impairment of alveolar macrophage phagocytosis (Baker et al., 1997, Trigo et al., 54 
1985), predisposes animals to more severe secondary bacterial and mycoplasma infections (Cusack 55 
et al., 2003, Kapil and Basaraba, 1997).   With the absence of severe clinical symptoms (Vaucher et 56 
al., 2008), infected animals may not be detected prior to the onset of more severe infections 57 
(AFBI/DAFM, 2012). Furthermore, routinely employed BPI3V-antibody ELISA cannot 58 
differentiate between vaccinated and infected animals, and by the time infected animals convalesce 59 
the virus has been cleared from the system and respiratory tract damage has already occurred.  60 
Molecular diagnostic techniques are hindered by the presence of vaccine derived genetic material, 61 
often requiring on-going virus amplification in order to generate sufficient genetic material for 62 
accurate diagnosis. Consequently, there are no commercial tests available for differentiation 63 
between BPI3V vaccinated and non-vaccinated animals. Anti-mortem diagnostic tests for BPI3V 64 
such as immunohistochemistry and virus isolation provide limited information on the current health 65 
status of an animal and can only determine pathogen exposure but not the presence of diseased 66 
tissue (Fulton and Confer, 2012), further illustrating the need for the development of alternative 67 
diagnostics capable of detecting infected animals (and the presence of diseased tissue) at early 68 
stages of infection.   69 
The development of biomarker based diagnostic tests relies on the detection of disease 70 
markers accumulated/released from localised tissues regions in circulating bio-fluids.  Primary cell 71 
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cultures offer a clean system that closely resembles relative tissue types for the identification of 72 
high confidence candidate markers for in vivo diagnostics.  With the death of BPI3V infected cells, 73 
proteins are released into the extracellular space and ultimately into circulating bio-fluids.  The 74 
detection of such markers would indicate not only the presence of viral infection but also damaged 75 
respiratory tissue, an indicator of underlying disease.  Suitable primary cell models to investigate 76 
BPI3V associated tissue damage include epithelial cells (the initial site of infection) and fibroblasts 77 
(the major component of lung interstitium and likely secondary site of infection following BPI3V 78 
release from epithelial cells). Whilst epithelial cells are the most promising cell types for candidate 79 
biomarker screening previous studies on Human Parainfluenza Virus-3 (hPIV-3) and the closely 80 
related paramyxovirus Respiratory Syncytial Virus (RSV) in A549 adenocarcinomic human 81 
alveolar basal epithelial cells have indicated an apoptotic response to infection, with an arrest in 82 
protein production (van Diepen et al., 2010, Brasier et al., 2004).  Such condidtions are 83 
unfavourable for biomarker screening which relies on the accumulation of disease specific markers 84 
within tissues and their eventual release into circulating biofluids.  Foetal Calf Lung (FCL) cells are 85 
known to facilitate in vitro growth of BPI3V (Shephard et al., 2003) and may provide conditions 86 
favourable for viral replication without shut down of host protein production, however little is 87 
understood about the interactions of BPI3V with respiratory fibroblasts at the intracellular level.  88 
Therefore, this study has set out to assess the proteomic responses of FCL cells during an in vitro 89 
BPI3V infection by 2 Dimensional Gel Electrophoresis (2D GE) profiling, and to determine 90 
whether identified candidate protein markers of in vitro infection can also be observed within the 91 
plasma of animals following in vivo infection. Such markers released from infected cells or diseased 92 
tissue, could be utilised to not only diagnose animals exposed to the viral pathogens but also 93 
determine virus induced respiratory tract damage and enable early treatment measures to be 94 
employed to prevent progression to more severe clinical disease states.    95 
  96 
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Materials and methods 97 
Chemicals and reagents 98 
GMEM, trypsin, gentamicin and glutamine were purchased from Invitrogen (Life Technologies, 99 
Paisley, UK).  Dithiothreitol (DTT), iodoacetamide (IAA), and Readysol IEF were purchased from 100 
GE Healthcare (Buckinghamshire, UK).  LC-MS grade formic acid, acetonitrile and H2O were 101 
purchased from Fisher Scientific (MA, USA).  All other reagents were electrophoresis grade and 102 
purchased from Fisher Scientific.  Sequencing grade modified trypsin was purchased from Promega 103 
(WI, USA).   104 
 105 
In vitro identification of candidate BPI3V protein biomarkers 106 
Cell culture and virus preparation 107 
Foetal Calf Lung (FCL) cells were prepared within the cell culture department of the Veterinary 108 
Science Division at the Agri-Food and Biosciences Institute, Northern Ireland.  Throughout this 109 
study FCL cells were maintained at 37ºC, 5% CO2 and adapted to low serum conditions via 110 
continuous passage in GMEM (supplemented with 1% glutamine, 0.1% gentamicin) with reducing 111 
foetal calf serum (FCS) concentration. Following adaption, cell viability and integrity was assessed 112 
by Alamar Blue (Invitrogen) and lactose dehydrogenase (LDH) (Roche, Basel, Switzerland) 113 
cytotoxicity assays using manufacturer’s protocols.   114 
 115 
Preparation of samples for in vitro biomarker screening 116 
FCL cells were seeded at a density of 6.25x105 cells per ml in 375ml culture flasks.  Cells were 117 
grown for 4 days until monolayered, then infected with BPI3V (isolate 2005/015033-Lung A – 118 
propagated in FCL cells (TCID50 10
8.2/ml)) a m.o.i. of 10:1 and incubated for 1hr.  Media was 119 
removed and cells washed 3 times with GMEM containing no FCS which was removed and 120 
replaced with GMEM containing 0.5% FCS.  Lysates were prepared from BPI3V infected FCL 121 
flasks at 24hrs and 48hrs (n=6) post-infection (p.i.).  27hrs prior to sample collection, media was 122 
6 
 
removed and cells washed 3 times over a period of 3hrs with GMEM containing no FCS.  Then 123 
washing media was removed and replaced with GMEM continuing no supplements.  After 24hrs  124 
culture media was removed from flasks and FCL monolayers washed twice with PBS and 1ml of 125 
Lysis buffer (7M Urea, 2M Thiourea, 4% CHAPS, Roche Protease Inhibitor (1 tablets per 10ml 126 
buffer) (Roche Applied Science, Lewes, East Sussex, United Kingdom) added and incubated for 127 
15min to facilitate cell lysis prior to protein concentration determination. Lysates were similarly 128 
prepared from uninfected cells (0hrs, n=6) as control. 129 
 130 
2D Gel Electrophoresis and image acquisition 131 
Cellular lysates were concentrated and desalted using 10kDa MW cut-off devices (Millipore, MA, 132 
USA) and 500µg of each sample was dissolved in rehydration buffer (final concentration 8M Urea, 133 
2% CHAPS, 0.5% IPG buffer, 0.002% bromophenol blue and 18mM DTT) and allowed to 134 
rehydrate overnight with IEF strips.  2D GE was performed using 13cm pH 3-10 non-linear IPG 135 
strips (GE Healthcare, Buckinghamshire, UK) in the first dimension and 12.5% SDS PAGE in the 136 
second dimension as described previously (Kinkead et al., 2015).  Gels were fixed and stained using 137 
the LSB colloidal staining method (Anderson et al., 1995), scanned using an Epson Perfection v750 138 
Pro scanner calibrated with a Monaco iT8 transparency reference target (iT8.7/1-1993 139 
MONT45:2010:12) and analysed using Ludesi REDFIN v3 software (Kafoo Group, Sweden).  Gel 140 
images from analysis of pooled samples were used as a reference for warping and spot matching - 141 
approximately 20 manual warping anchors were applied to all gels prior to automatic alignment.   142 
Spot borders and locations were manually refined to ensure accurate location and matching prior to 143 
spot selection.   144 
 145 
Mass-spectrometry analysis of protein gel spots 146 
Gel spots were excised using a Gelpal spot cutter (Genetix) from pooled FCL lysates (comprised of 147 
an equal amount of all samples, n=3) and in gel digestion was performed using modifications to a 148 
7 
 
previously described protocol (Shevchenko et al., 2006).  Digests were evaporated to dryness using 149 
a MiVac Quattro Concentrator operating under aqueous settings for 4hr at 30ºC.  Tryptic peptides 150 
were resuspended in 12µl of a 0.1% formic acid, 2% acetonitrile solution and analysed using a 151 
Thermo Scientific LTQ ORBITRAP XL mass spectrometer connected to a Dionex Ultimate 3000 152 
(RSLCnano) chromatography system.  Each sample was loaded onto a Biobasic Picotip Emitter 153 
(120mm length, 75μm ID) packed with Reprocil Pur C18 (1.9μm) reverse phase media column and 154 
separated by an increasing acetonitrile gradient, using a 19min reverse phase gradient at a flow rate 155 
of 250nL/min. The mass spectrometer was operated in positive ion mode with a capillary 156 
temperature of 200°C, a capillary voltage of 31V, a tube lens voltage of 85V and with a potential of 157 
1900V applied to the frit.  All data was acquired with the mass spectrometer operating in automatic 158 
data dependent switching mode. A high-resolution MS scan (mass range of 300-2000Da) was 159 
performed using the Orbitrap to select the 7 most intense ions prior to MS/MS analysis using the 160 
Ion trap.  161 
 162 
Protein identification and functional classification 163 
Raw mass spectrometry data was processed and de novo peptide analysis performed using PEAKS 164 
Studio version 6 (Bioinformatics Software Inc.).  Parent mass tolerance and fragment ion error were 165 
set at 20ppm and 1.0Da respectively.  A maximum of 3 missed cleavages and 1 non-specific 166 
cleavage were allowed. A fixed Post Translational Modifications (PTM) of carbamidomethylation 167 
was selected and a maximum of 3 variable PTMs per peptide. Peptides were searched against a 168 
combined Uniprot Bos Taurus and Bovine Parainfluenza Virus-3 database.  A false discovery rate 169 
of 1% was applied with the requirement of at least 1 unique peptide per protein match.  Correct 170 
identification was only allowed for peptides that corresponded to a protein with matching molecular 171 
weight and pI on 2D gels.  The Panther database (version 8.1, http://www.pantherdb.org/) was used 172 
for functional classification of identified proteins.  As the bovine proteome lacks high-level 173 
annotation as compared to the human proteome, missing functional classifications were determined 174 
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based on human homologues.  Where functional classification could not be determined using 175 
Panther, AmiGO (version 1.8, http://amigo.geneontology.org/cgi-bin/amigo/go.cgi) experimental 176 
evidence code gene ontology annotations were selected.  177 
 178 
In vivo assessment of candidate BPI3V protein biomarkers  179 
BPI3V infection protein marker candidates selected from in vitro proteomic analysis were screened 180 
in bio-banked plasma samples from BPI3V challenged vaccinated and non-vaccinated calves (Gray 181 
et al., 2015). 182 
 183 
In-solution tryptic digestion of proteins for targeted MRM analysis by UPLC-MS/MS 184 
10µl of 1µM yeast ADH (internal recovery control) and 20µl of plasma was diluted to a final 185 
volume of 100µl with 100mM ammonium bicarbonate.  Samples were reduced with 10µl of 186 
100mM DTT, 100mM ammonium bicarbonate for 60ºC for 30mins followed by alkylation with 187 
10µl of 200mM iodoacetamide, 100mM ammonium bicarbonate for 1hr.  50µl of Promega 188 
sequencing grade trypsin (80µg/ml in 10% acetonitrile, 10mM ammonium bicarbonate) was added 189 
and samples were incubated at 37ºC for 16hrs. 10µl of 10% formic acid was then added to stop the 190 
reaction and peptides were purified and concentrated by C18 solid phase extraction (SPE) using an 191 
Empore C18 96 well solid phase extraction (SPE) plate (Sigma Aldrich).  The resin was conditioned 192 
with 100µl of 0.1% formic acid, 99.9% acetonitrile and washed twice with 200µl 0.1% formic acid 193 
(wash buffer) prior to addition of digested samples.  The plate was washed with 200µl of wash 194 
buffer and peptides eluted with three washes of 150µl 0.1% formic acid, 60% acetonitrile. The 195 
combined eluates were dried using a MiVac (GeneVac) operating at 40ºC H2O.     196 
 197 
Targeted MRM analysis of peptides by UPLC-MS/MS 198 
In silico peptide fragmentation and selection of MRM transitions (Supplementary File 1) was 199 
performed using Skyline (MacLean et al., 2010) and BLAST search performed by MRMpath 200 
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(Crasto et al., 2013).  Dried peptides were reconstituted in 20µl 0.1% formic acid, 3% acetonitrile, 201 
96.9% H2O and 8µl of sample was injected onto an ACQUITY UPLC® CSHT130 C18 column 202 
(100mm x 2.1mm i.d., 1.7µm, 130Å; Waters Corporation, Milford, MA, USA).  Column and 203 
autosampler temperature were maintained at 30ºC and 8ºC respectively, and chromatographic 204 
separation performed at a flow rate of 100µl/min with mobile phase consisting of 99.9% H2O, 0.1% 205 
formic acid (A) and 99.9% Acetonitrile, 0.1% formic acid (B).  The elution gradient was as follows: 206 
0 – 1 min isocratic at 1% of B, 1 – 30 min linear gradient from 1 - 45% of B, 30 – 31 linear gradient 207 
from 45 - 95% of B, 31 – 33 min isocratic at 95% of B, 33 min at isocratic 1% B and finally 33 – 35 208 
min isocratic at 1% of B.  Mass spectrometry was performed using a Waters Quattro Premier QqQ 209 
operating in positive-ion mode (ESI+) with the capillary voltage set to 3000V and the sampling 210 
cone voltage 35V.  The desolvation, collision and cone gas flows were set at 500 L/h, 0.3 ml/min 211 
and 50 L/h respectively.  Source and desolvation temperatures were 120ºC and 400ºC respectively.  212 
Inter-channel and inter-scan delay were maintained at 0.005s, scan range at 0.5Da, and dwell at 213 
0.025s for all peptides.     214 
 215 
Statistical analysis 216 
Two-way ANOVA with post-hoc bonferroni test was applied for the analysis of FCS media content 217 
and BPI3V infection in Alamar Blue cell viability and LDH cell cytotoxicity assays.  Significantly 218 
different protein spots were selected using ANOVA within Ludesi Redfin software.  Linear and 219 
non-linear regression for protein quantification and correlation between estimated and identified 220 
protein MW and pI was performed using Prism Graphpad version 5.  SIMCA version 13 (Umetrics) 221 
was employed for multivariate statistical analysis of spot volumes obtained from 2D GE.  Principle 222 
component analysis was applied to Pareto scaled data, excluding spots with %CV greater than 50%.  223 
For targeted peptide analysis by UPLC-MS, ANOVA with bonferroni post-hoc test was performed 224 
for statistical analysis using Prism Graphpad (version 5).  Statistical analysis of temporal changes in 225 
protein levels between experimental groups throughout the study was assessed using a paired two-226 
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tailed t-test.  TargetLynx was used for the extraction of raw data and analysis.  Integration 227 
parameters were: retention time window 0.2 min, mean smoothing, width 3, 3 iterations, automatic 228 
apex peak tracking and integration window extend of 5.  Peak area values for the respective 229 
peptides were corrected using the peak area of internal trypsin self-digestion products and spiked 230 
yeast ADH was employed to assess peptide recovery.  ADH standards in the range of 100µM to 231 
10nM facilitated the relative quantification of protein levels in plasma. 232 
 233 
Results 234 
In vitro identification of candidate BPI3V markers of infection 235 
Optimization of in vitro models for BPI3V infection studies 236 
Adaption of FCL cells to low serum growth conditions (to minimize contamination of cell lysates 237 
with serum derived proteins) had no negative impact on viability or integrity of cells throughout the 238 
sample collection period (Supplementary File 2).  Increased cytotoxicity and decreased cell viability 239 
were observed as a result of BPI3V infection at 72hrs p.i. thereby restricting the sampling period to 240 
48hrs p.i. 241 
 242 
Identification of in vitro BPI3V infection markers by 2D GE analysis of FCL lysates 243 
Figure 1 illustrates representative gel images obtained following 2D GE analysis of mock/BPI3V 244 
infected FCL lysates. 2D gels revealed excellent protein separation and resolution by pI and MW, 245 
with an average of 738 spots detected within FCL lysates across all gels. Spots identified visually as 246 
being significantly different within infected compared to control FCL cells are indicated. 57 spots 247 
were found to have fold change (FC) >1.5 (up- or down-regulated relative to 0hrs mock infected 248 
FCL cells) and p<0.05 from one-way ANOVA (performed in Ludesi software) (Supplementary File 249 
3), representing an alteration of 19% of detectable proteins in response to BPI3V infection.  These 250 
spots (illustrated in Figure 1) were selected for protein identification by liquid chromatography 251 
mass spectrometry (LC-MS). 252 
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  253 
LC-MS identification of differentially expressed protein spots 254 
The identity and sequence coverage of the 57 spots analysed by LC-MS are illustrated in Table 1. 255 
The estimated MW and pI of selected spots were determined by matching against a reference gel 256 
map for MRC-5 fibroblasts (Rubporn et al., 2009).  Data analysis was performed using Peaks 257 
Studio (version 6) and 53 of 57 spots submitted for LC-MS were identified against a combined 258 
Uniprot KB Bos taurus and BPI3V database.  Blast searching revealed at least 1 unique peptide 259 
sequence per protein, with average sequence coverage of 26.5% (ranging from 1-89%).  These 260 
annotations correspond to 35 unique proteins with a number of protein isomers detected as indicated 261 
by varying estimated pI (Table 2).  Surprisingly, the only BPI3V related protein significantly altered 262 
was Phosphoprotein P (9 isomers with isoelectric points ranging from pI 5.2 to 5.9).  However, 263 
other BPI3V proteins may have be present but did not pass marker selection criteria (FC > 1.5, p < 264 
0.05 and high spot volume for MS/MS) or were poorly resolved membrane proteins 265 
(haemagglutinin neuraminidase and fusion glycoprotein) a known limitation of 2D GE.  This 266 
protein was observed to be the second most abundant protein within cells at 48hrs p.i. (Figure 1), 267 
with only actin having a slightly higher spot volume.  Furthermore, gel spots corresponding to T-268 
complex proteins 1 subunit theta and 14-3-3 protein were significantly up-regulated in BPI3V 269 
infected cells during the latter stages of infection (48hrs p.i.) with high intracellular abundance 270 
(Figure 1D).  There was a significant (p<0.001) correlation between the estimated and database 271 
protein pI (R2 = 0.9887) and MW (R2 = 0.875) values for spots characterised by LC-MS, 272 
confirming reliability in the identities conferred on selected proteins.  273 
 274 
Functional classification of differentially expressed markers of in vitro BPI3V infection 275 
Table 2 illustrates the functional classification, biological process and subcellular location of 276 
identified proteins determined using the Gene Ontology tools PantherDB and AMIGO.  The 277 
proportional subcellular location of all differentially expressed proteins in FCL cells following 278 
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BPI3V infection is illustrated in Figure 2A. The majority of proteins were associated with either 279 
cytoplasmic, nuclear or cytoskeletal sub-cellular locations, with a small number originating from 280 
organelles and only collagen alpha 1 found to exist in the extracellular matrix as a secretory protein.     281 
 Figure 2B&C and Figure 2D&E illustrate the biological processes and molecular functions 282 
respectively of differentially expressed proteins.  The majority of up-regulated proteins are involved 283 
in metabolic, cellular and developmental processes, and on closer inspection these proteins have 284 
key roles in mRNA translation, protein synthesis and post-translational modification as well as 285 
intracellular protein transport (Table 2 and Figure 2B and D).  Furthermore, the only identified 286 
proteins involved in immune system processes were heat shock proteins 27kDa and 70kDa.  Down-287 
regulated proteins were associated with a wide range of biological processes, however 33% of the 288 
molecular functions were associated with structural molecule activity and upon closer inspection of 289 
Uniprot KB annotation these proteins were involved in maintaining cellular, sub-cellular and extra-290 
cellular structures.    291 
Proteins which were down-regulated at 24hrs and 48hrs p.i. as a result of BPI3V infection 292 
(collagen alpha 1, Heat shock 27kDa protein 1, and PDZ and LIM domain protein 1) are involved in 293 
supporting cellular structures in stress conditions and trafficking proteins to the cytoskeleton based 294 
on Gene Ontology (GO) annotation.  At 24hrs and 48hrs p.i. a number of down-regulated proteins 295 
share biological functions associated with maintenance of cell morphology (Ezrin and Lipoma 296 
Preferred Partner) and in cytoskeleton regulation (LIM and SH3 protein domain protein 1).  The 297 
protein down-regulation observed in latter stages of infection is not surprising and is likely to be 298 
associated with the visible changes in cell morphology reported in BPI3V infected cells (including 299 
detachment of cell monolayers and pyknosis, loss of cilia, intracytoplasmic inclusion bodies and 300 
syncytium formation (Campbell et al., 1969).  Between 24hrs to 48hrs p.i. different expression 301 
profiles were only observed for 3 proteins:  Proteasome subunit alpha type-5, 14-3-3 protein theta 302 
and 60S acidic ribosomal protein p0.  The proteins up-regulated as a result of BPI3V infection are 303 
involved in a number of biological processes relating to protein production translation 304 
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(Nucleophosmin, Eukaryotic translation initiation factors 2 and 6, 60S ribosonal protein p0), protein 305 
folding (T-complex protein 1 subunit theta, Protein Disulphate Isomerase A3, Tubulin Specific 306 
Chaperone E), protein modification (Proteasome subunit beta type, Proteasome subunit alpha type 307 
5, GANAB, aspartyl aminopeptidase), and protein trafficking (Annexin) (Table 2).  Furthermore, 308 
BPI3V infection resulted in an up-regulation of proteins involved in the maintenance of cell 309 
structure (Fascin, Lamin A/C, Moesin, L-caldesmon, non-muscle myosin heavy chain, calponin-3) 310 
and cell signalling (14-3-3 protein beta/alpha/theta, cystathionine gamma lyase, osteoclast 311 
stimulating factor 1).  Finally, up-regulated isocitrate dehydrogenase and 6-312 
phosphogluconolactonase catalyse the reactions that produce NADPH and NADH, which are 313 
necessary for a number of reducing reactions such as post-translational protein modification 314 
(Smolkova and Jezek, 2012).  Taken, these altered protein relationships in response to infection 315 
may reflect the exploitation of the host cell to aid the replication of viral proteins and transport to 316 
the cell membrane for budding. 317 
 318 
Quantification of selected protein markers of in vitro BPI3V infection within plasma of BPI3V 319 
challenged animals 320 
Targeted proteomic analysis was performed to assess changes in the levels of Phosphoprotein P, 14-321 
3-3 protein beta/alpha and T-complex protein subunit theta as these are proteins found in high 322 
abundance during the latter stages of infection by proteomic analysis of in vitro infected cells and 323 
have the potential to be released from infected tissues into circulating biofluids.  Yeast ADH 324 
loading controls demonstrated low variability (CV=11.6 and excellent recovery (96%) following 325 
SPE and no significant differences in spiked ADH levels were observed between vaccinated and 326 
non-vaccinated animals at any stage throughout the study. Proteotypic peptides for Phosphoprotein 327 
P and T-complex protein subunit theta were detected and quantified within plasma at days 0, 1, 2, 5, 328 
6, 14 and 20 post-BPI3V challenge in both vaccinated and non-vaccinated study groups. However, 329 
no peptides corresponding to 14-3-3 protein beta/alpha were detectable in plasma at any time point.  330 
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Unique peptides for phosphoprotein P and T-complex protein 1 subunit theta were found to be 331 
significantly (p<0.05) up-regulated at day 5 p.i. in non-vaccinated animals compared to vaccinated 332 
animals at the same stage as illustrated in Figure 3.  Plasma levels of Phosphoprotein P (Figure 3A) 333 
were found to increase significantly (p<0.05) from day 1 to day 5 post-BPI3V challenge in non-334 
vaccinated animals.  335 
 336 
  337 
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Discussion  338 
Lysates obtained from mock and BPI3V infected FCL cells were profiled by 2D Gel 339 
Electrophoresis to assess host cell proteome responses to BPI3V infection and identify potential in 340 
vivo infection markers of diagnostic potential. 57 proteins spots were significantly altered in FCL 341 
cells as a result of BPI3V infection, corresponding to 35 unique protein identifications. Whilst to 342 
date there are no reports relating the effects of BPI3V infection on the intracellular proteome or the 343 
proteomic effects of paramyxoviruses on respiratory fibroblasts, intracellular proteomic responses 344 
to Human Parainfluenza Virus-3 (hPIV-3) (van Diepen et al., 2010) and Respiratory Syncytial 345 
Virus (RSV) (Brasier et al., 2004, Munday et al., 2010, van Diepen et al., 2010, Hastie et al., 2012, 346 
Ternette et al., 2011) infections have been investigated.  Such studies have reported similar findings 347 
to the current investigation, with an up-regulation of lamin A/C (van Diepen et al., 2010) 20, 22], 348 
nucleophosphim (van Diepen et al., 2010), protein disulphate isomerase A3 (PDIA3) (Hastie et al., 349 
2012), indicating host-cell immune responses to BPI3V infection - as PDIA3 mediates MCH class I 350 
peptide presentation and lamin A/C represses viral replication (Mou et al., 2008).  In A549 351 
respiratory epithelial cells paramyxovirus infection resulted in an up-regulation of host-proteins 352 
linked to apoptotic processes and a shut-down of transcription, RNA processing and protein 353 
biosynthesis (van Diepen et al., 2010, Munday et al., 2010).  However, this study’s findings indicate 354 
that BPI3V does not induce complete shut-down of host protein synthesis or apoptosis in 355 
fibroblasts, resulting in virus-host mRNA competition for virus propagation.  Fibroblast pro-356 
inflammatory response to UV inactivated virus has been observed due to stress mediators present in 357 
HeLa propagation cultures (Bedke et al., 2009, Oliver et al., 2006), however, no such pro-358 
inflammatory response was observed in this study.  As FCL fibroblasts were employed for BPI3V 359 
propagation the model system for biomarker screening employed closely reflects that which occurs 360 
in vivo - i.e. the presence of not only virus induced protein changes but also the stress response 361 
from surrounding tissue sites.  Furthermore, any stress response markers produced during viral 362 
replication should closely match the in vivo response within the lung interstitium, and therefore as a 363 
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model of determining BPI3V candidate markers this study closely matches in vivo conditions in 364 
specific tissue regions.  An increase in the levels of proteins associated with RNA translation, 365 
protein folding and post-translational-modification were observed in BPI3V infected fibroblasts.  366 
Up-regulated annexin A11, previously observed inside influenza virions (Shaw et al., 2008) and 367 
thought to play a role in virus assembly, could be assisting trafficking of viral proteins to the plasma 368 
membrane and budding.  These observations suggest that fibroblasts respond to BPI3V infection by 369 
increasing the production of proteins to combat the competitive effects of viral mRNA and the 370 
associated demand for protein folding and protein modification.  Furthermore, the down-regulation 371 
of key intra- and extra-structural proteins reflects how BPI3V infection induces changes in cell 372 
morphology.   373 
Phosphoprotein P, T-complex protein 1 subunit theta and 14-3-3 protein beta/alpha, levels 374 
of which were significantly increased within BPI3V infected FCL cells, were selected as potential 375 
diagnostic markers of in vivo BPI3V infection.  Whilst other proteins involved in anti-viral immune 376 
response mechanisms were significantly altered in BPI3V infected cells (e.g Lamin A/C and 377 
PDIA3) they were not selected due to lower intracellular abundance and associated reduced chance 378 
for detection in circulating bio-fluids.  Phosphoprotein P is involved in the assembly of viral RNA 379 
polymerase complex and is associated with intracellular defence avoidance (Gale and Katze, 1998) 380 
through shutdown of host cell protein production (Gainey et al., 2008, Komatsu et al., 2007).  381 
Transcriptional activity of BPI3V proteins is highest at 3’ region, and as Phosphoprotein P occurs in 382 
the second ORF (Vainionpää and Hyypiä, 1994), its expression is elevated relative to other BPI3V 383 
viral proteins. A high intracellular abundance of Phosphoprotein P has been reported previously in 384 
studies performing 2D GE investigations of other paramyxoviruses (Hastie et al., 2012).  However, 385 
within virions Phosphoprotein P represents only a small proportion of total protein (Ellis, 2010), 386 
and a significant quantity of free Phosphoprotein P may not be encapsulated within budding virions. 387 
A high level of free Phosphoprotein P may therefore be released into the circulatory system as 388 
infected cells die making it detectable as a marker of tissue death.  Such diagnostic approaches 389 
17 
 
based on proteins released from infected cells have previously been employed for Dengue and 390 
West-Nile Virus (Alcon et al., 2002, Yeh et al., 2012), enabling rapid identification of infected 391 
individuals prior to antibody response and differentiation of live virus antibody responses from 392 
inactivated virus vaccines.  Molecular chaperone T-complex protein 1 subunit theta and 393 
signalling/binding protein 14-3-3 protein beta/alpha were also found to be accumulated within cells 394 
at the latter stages of in vitro infection, and might be candidate markers of tissue damage in vivo.  395 
Targeted multiple-reaction-monitoring (MRM) tandem mass spectrometry (MS/MS) 396 
analysis was performed to determine the presence or otherwise of proteins identified through in 397 
vitro analysis within plasma of vaccinated and non-vaccinated animals challenged with BPI3V and 398 
to assess their potential as diagnostic markers of in vivo infection. Unique peptides corresponding to 399 
Phosphoprotein P and T-complex protein 1 subunit theta were detected in bovine plasma, however 400 
14-3-3 protein beta/alpha could not be detected.  Levels of Phosphoprotein P and T-complex protein 401 
1 subunit theta were significantly up-regulated in non-vaccinated animals compared to those 402 
vaccinated at day 5 post BPI3V challenge.  Peak BPI3V titre in vivo has been demonstrated to occur 403 
between days 4 to 6 p.i., and furthermore, vaccinated animals respond quicker, clearing the 404 
infections rapidly (Xue et al., 2010).  In particular for Phosphoprotein P, increasing levels in non-405 
vaccinated animals from day 0 to day 5 p.i. compared to vaccinated animals, mirrors that of viral 406 
shedding observed in vaccinated animals compared to non-vaccinated, i.e. virus titre peaking at 407 
days 4-6 p.i. in non-vaccinated animals and days 1-2 p.i. in vaccinated animals (Xue et al., 2010).  408 
This is not surprising as when more infected cells die, increased levels of intracellularly 409 
accumulated Phosphoprotein P and T-complex protein 1 subunit theta will be released into the 410 
circulation.  However, the levels of both these proteins dropped from day 5 to 6 post-BPI3V 411 
challenge in non-vaccinated animals. These findings indicate that it is possible that these proteins 412 
are rapidly degraded in the circulation and although their presence in plasma is an indicator of a 413 
specific virus induced damage to the respiratory tract there may be a limited window for their useful 414 
diagnostic application.  415 
18 
 
In conclusion, this study has demonstrated that proteomic analysis of BPI3V infection in 416 
vitro is capable of identifying protein infection markers, which subsequently are detectable in 417 
plasma of animals following BPI3V infection.  BPI3V induced alterations to the intracellular 418 
proteome of respiratory fibroblasts resulted in elevated levels of host-proteins associated with 419 
mRNA translation, protein translation, post-translational modification and cellular protein 420 
trafficking.  Viral (Phosphoprotein P) and host (T-complex protein 1 subunit theta) proteins 421 
accumulated intracellularly during the latter stages of infection may be released into the circulation, 422 
and elevated levels were found to occur in plasma of non-vaccinated BPI3V challenged animals at 423 
periods associated with peak virus titre. Compared to serological ELISA, which relies on the 424 
measurement of a single parameter (antibodies), assessment of such protein markers would provide 425 
increased information on the health status of pre-convalescent animals during infection outbreaks, 426 
or verify absence of sub-clinical disease in those identified as seropositive. Further research is 427 
needed to validate these markers on a larger scale and to develop more applicable diagnostic tests 428 
which can quantify protein levels in routine analysis. The utilisation of such markers diagnostically 429 
would improve disease management decisions through the identification of animals undergoing 430 
active BPIV3 infection and the presence of necrotic tissue, a major risk factor for the development 431 
of more severe bacterial pneumonia. Such a proteomic approach to the identification of markers of 432 
infection may also be relevant to other viruses which persist for longer periods within hosts offering 433 
longer useful diagnostic windows.  434 
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sequence database for the identification.  Spots were matched based on MW and pI calibration from 563 
gels.  FC = fold change, p = significance (one-way ANOVA). 564 
 565 
Table 2: Classification of biological processes, molecular functions and subcellular locations 566 
of the identified differentially expressed proteins.  The Panther database (version 8.1, 567 
http://www.pantherdb.org/) was used for functional classification of identified proteins.  Where 568 
functional classification could not be determined using Panther, AmiGO (version 1.8, 569 
http://amigo.geneontology.org/cgi-bin/amigo/go.cgi) experimental evidence code gene ontology 570 
annotations were selected.  Subcellular location was determined from Uniprot KB annotation.  As 571 
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the bovine reference database is small, where annotation was not possible human homologues 572 
substituted. 573 
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Figure 1: Representative images of control and BPI3V infected FCL cells at 24hrs and 48hrs 575 
p.i.   Cell lysates from (A) control, (B) 24hr post-BPI3V infection and (C) 48hr post-BPI3V 576 
infection FCL cells were analysed by 2D Gel Electrophoresis using 13cm pH 3-10 NL IPG strips in 577 
the first dimension and 12.5% SDS-PAGE lab cast gels in the second dimension.  Gels were 578 
scanned using an Epson v750 Pro scanner and spot matching, warping and statistical analysis 579 
performed using Ludesi Redfin.  Differentially expressed protein spots are indicated with circles on 580 
each gel.  (D) The 3D spots for the proteins 14-3-3protein beta/alpha, Phosphoprotein P and T-581 
complex protein 1 subunit theta at each sampling point are indicated.  Gel image adjustments were 582 
performed automatically by Ludesi Redfin. 583 
 584 
Figure 2: Subcellular location, biological processes and molecular function of differentially 585 
expressed FCL cell proteins as a result of BPI3V infection.  Subcellular location, was 586 
determined from UniprotKB annotation for the proteins selected by 2D GE and identified by LC-587 
MS.  Biological processes and molecular function was determined from Gene Ontology analysis 588 
performed using Panther DB (and AMIGO where no annotation was available).  As the bovine 589 
reference database is small, where annotation of subcellular location was not possible human 590 
homologues substituted. 591 
 592 
Figure 3:  Quantification of Phosphoprotein P and T-Complex Protein 1 Subunit Theta 593 
markers for BPI3V infection by UPLC-MS/MS.  At day 0-6 p.i. (n=6) and day 14-20 p.i.(n=3). 594 
Values represent mean ± S.E.M.  Relative quantification of the peptide markers was performed by 595 
interpolating the average peptide intensity (integrated peptide area) and normalizing against trypsin 596 
auto digestion products (fixed volume of trypsin per sample added prior to C18 SPE) to account for 597 
variations in recovery. 598 
 599 
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 1 
Description Uniprot I.D Spot ID 
Estimated Database Identification 
Comparison to control 
24hr p.i. 48hr p.i. 
MW (Da) pI MW (Da) pI Accession -10lgP Coverage (%) # Peptides # Unique FC p FC p 
Collagen alpha-1(III) chain F1MXS8_BOVIN 
358 139000 6.20 
138928 6.32 
F1MXS8_BOVIN 215.04 8 11 11 -18.19 1.15E-02 -38.36 1.03E-02 
415 139000 6.10 F1MXS8_BOVIN 222.76 6 8 8 -15.41 1.07E-02 -38.53 9.37E-03 
Collagen alpha-1(I) chain CO1A1_BOVIN 
210 138300 5.60 
138939 5.60 
CO1A1_BOVIN 209.49 10 14 14 -7.94 1.50E-02 -19.58 1.12E-02 
359 138200 5.50 CO1A1_BOVIN 194.18 8 12 12 -4.23 2.05E-03 -6.00 1.22E-03 
Heat shock 27kDa protein 1 E9RHW1_BOVIN 42 23700 6.00 22393 5.98 E9RHW1_BOVIN 221.6 89 26 26 -3.08 1.58E-02 -2.63 2.14E-02 
PDZ and LIM domain 1 A6H7E3_BOVIN 509 37600 6.80 35821 6.76 A6H7E3_BOVIN 78.37 6 2 2 -2.08 3.41E-02 -3.37 1.27E-02 
Lipoma-preferred partner E1BMD6_BOVIN 82 66600 7.70 65715 7.44 E1BMD6_BOVIN 61.6 2 1 1     -3.56 8.55E-03 
LIM and SH3 domain protein 1 LASP1_BOVIN 102 31600 7.60 29677 7.07 LASP1_BOVIN 115.59 14 4 4     -3.21 4.19E-03 
Ezrin EZRI_BOVIN 264 68000 6.30 68760 6.07 EZRI_BOVIN 171.82 19 13 13     -3.98 8.54E-03 
Proteasome subunit alpha type-5 PSA5_BOVIN 185 25900 4.70 26411 4.74 PSA5_BOVIN 71.4 5 1 1 -2.04 4.08E-02 5.36 1.75E-02 
14-3-3 protein theta 1433T_BOVIN 2 27000 4.60 27764 4.80 1433T_BOVIN 80.11 21 7 4 -1.95 4.84E-03 14.85 1.13E-02 
60S acidic ribosomal protein P0 RLA0_BOVIN 338 34000 6.00 34371 5.70 RLA0_BOVIN 204.13 31 8 8 -1.76 3.72E-02 2.01 3.22E-02 
Aspartyl aminopeptidase DNPEP_BOVIN 132 51700 7.50 51828 6.45 DNPEP_BOVIN 207.84 27 10 10 1.52 4.55E-02     
Fascin Q3MHK9_BOVIN 125 54100 6.60 54785 6.50 Q3MHK9_BOVIN 269.33 49 29 29 1.69 1.68E-02     
Lamin A/C Q3SZI2_BOVIN 79 63000 6.80 65122 6.54 Q3SZI2_BOVIN 192.44 27 17 17 2.13 3.24E-02     
GANAB protein A6QNJ8_BOVIN 330 90000 5.80 109085 5.74 A6QNJ8_BOVIN 158.36 11 12 12 2.01 2.29E-02     
Tubulin-specific chaperone E TBCE_BOVIN 458 61200 6.20 59327 5.97 TBCE_BOVIN 177.65 21 11 11 2.13 1.28E-02     
Serine hydroxymethyltransferase GLYM_BOVIN 419 55000 7.70 55606 6.51 GLYM_BOVIN 302.28 53 24 24 2.29 1.32E-03     
Annexin A11 ANX11_BOVIN 227 55000 7.70 54018 7.53 ANX11_BOVIN 194.76 34 17 17 1.96 1.36E-02     
Moesin MOES_BOVIN 318 66500 6.00 67975 5.91 MOES_BOVIN 138.2 11 9 9 1.75 3.51E-03 1.73 9.37E-03 
Eukaryotic translation initiation factor 2 subunit 1 F2A_BOVIN 573 36000 4.80 36108 5.02 F2A_BOVIN 217.29 29 10 10 1.76 2.91E-02 2.30 3.00E-03 
L-caldesmon Q8HYY3_BOVIN 110 67800 6.10 62086 6.24 Q8HYY3_BOVIN 232.35 29 17 17 1.63 1.20E-02 1.84 6.81E-04 
Osteoclast-stimulating factor 1 OSTF1_BOVIN 40 23700 5.20 23842 5.30 OSTF1_BOVIN 129.72 15 3 3 2.74 7.81E-05 10.08 7.84E-03 
T-complex protein 1 subunit theta 
TCPQ_BOVIN 138 57900 5.40 59610 5.39 TCPQ_BOVIN 165.76 12 7 7 5.37 2.62E-06 14.22 2.59E-03 
TCPQ_BOVIN 133 58300 5.40 59610   TCPQ_BOVIN 259.08 39 19 19 2.85 5.23E-03 10.72 1.10E-02 
BPI3V Phosphoprotein P 
E5LP67_PI3B 27 68100 5.20 67770 
5.58 
E5LP67_PI3B 317.64 35 29 19 8.73 8.76E-05 43.66 1.63E-03 
E5LP67_PI3B 182 68200 5.70 67770 E5LP67_PI3B 235.92 28 19 1 12.89 3.45E-05 19.22 9.17E-03 
E5LP67_PI3B 92 68100 5.60 67770 E5LP67_PI3B 330.89 46 34 5 13.91 1.55E-03 32.23 1.90E-03 
E5LP67_PI3B 44 68000 5.30 67710 L0HCM6_PI3B 258.68 27 18 0 17.79 4.97E-05 70.50 1.91E-03 
E5LP67_PI3B 47 68000 5.40 67770 E5LP67_PI3B 356.71 37 30 21 39.26 1.62E-04 115.92 1.88E-03 
B2C5X6_PI3B 401 67100 5.70 66460 B2C5X6_PI3B 200.25 13 8 1 52.55 1.25E-04 142.08 7.15E-03 
E5LP67_PI3B 819 67700 5.20 67770 E5LP67_PI3B 308.16 47 35 5 4.16 3.77E-04 30.94 1.57E-02 
E5LP67_PI3B 255 67400 5.90 67710 L0HCM6_PI3B 61.73 1 1 1 1.57 3.42E-02 2.28 2.75E-04 
E5LP67_PI3B 235 68100 5.80 67770 E5LP67_PI3B 248.51 25 15 15 2.70 1.46E-04 4.02 1.96E-04 
Protein disulfide-isomerase A3 
A5D7E8_BOVIN 333 58000 5.70 56930 5.78 PDIA3_BOVIN 76.9 6 3 3 2.08 8.76E-03 13.32 1.26E-02 
A5D7E8_BOVIN 25 56800 6.40 56930   A5D7E8_BOVIN 347 62 42 42     2.93 2.35E-02 
Annexin I6YIV1_BOVIN 16 37300 6.30 38992 6.37 I6YIV1_BOVIN 309.26 62 27 27     2.95 7.07E-03 
Non-muscle myosin heavy chain O02717_BOVIN 48 72400 5.20 72371 5.02 O02717_BOVIN 354.67 52 41 2     5.07 7.08E-03 
Nucleophosmin E3SAZ8_BOVIN 57 32200 4.70 32201 4.20 E3SAZ8_BOVIN 176.18 27 6 6     2.82 2.19E-02 
6-phosphogluconolactonase F1MM83_BOVIN 62 28200 5.40 27531 5.57 F1MM83_BOVIN 150.98 15 3 3     4.02 8.53E-03 
14-3-3 protein beta/alpha 1433B_BOVIN 111 26600 4.70 28081 4.80 1433B_BOVIN 112.17 17 4 2     6.60 2.16E-04 
Cystathionine gamma-lyase E1BNH2_BOVIN 134 40100 6.10 44380 6.01 E1BNH2_BOVIN 153.36 22 8 8     1.29 4.97E-02 
Phosphoserine phosphatase SERB_BOVIN 158 24900 5.20 24850 5.20 SERB_BOVIN 164.75 27 6 6     2.37 1.82E-02 
Heat shock 70 kDa protein 
HS71B_BOVIN 5 64600 5.20 70229 
5.20 
HS71B_BOVIN 336.85 42 35 21     2.16 7.84E-03 
HSP7C_BOVIN 166 64900 5.20 71241 HSP7C_BOVIN 322.6 47 29 18     2.38 1.78E-02 
Proteasome subunit beta type F1MBI1_BOVIN 272 27300 6.10 29996 6.44 F1MBI1_BOVIN 169.83 34 11 11     1.58 4.63E-03 
Calponin-3 CNN3_BOVIN 357 36000 5.40 36358 5.42 CNN3_BOVIN 182.15 26 7 7     1.65 1.41E-02 
Isocitrate dehydrogenase [NAD] subunit alpha IDH3A_BOVIN 481 39300 5.80 39668 5.80 IDH3A_BOVIN 77.86 5 2 2     1.68 2.99E-02 
Eukaryotic translation initiation factor 6 IF6_BOVIN 532 25900 4.60 26513 4.60 IF6_BOVIN 171.54 22 4 4     3.16 1.61E-02 
 2 
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Description Spot ID 
Relationship to control 
Biological process Molecular function Subcellular Location 
24hr p.i. 48hr p.i. 
Collagen alpha-1(III) chain 358;415 DOWN DOWN 
Receptor activity; extracellular matrix structural 
constituent; transmembrane transporter activity 
Macrophage activation; blood circulation;intracellular protein transport; receptor-mediated 
endocytosis; signal transduction; cell-cell adhesion; cellular component morphogenesis; ectoderm 
development; mesoderm development; skeletal system development; angiogenesis; regulation of 
liquid surface tension; defense response to bacterium; asymmetric protein localization 
Secreted; extracellular matrix 
Collagen alpha-1(I) chain 210;359 DOWN DOWN 
Heat shock 27kDa protein 1 42 DOWN DOWN Structural molecule activity 
Immune system process;muscle contraction; visual perception; sensory perception; protein 
folding; response to stress 
Cytoplasm; cytoskeleton; 
nucleus 
PDZ and LIM domain 1 509 DOWN DOWN 
Structural constituent of cytoskeleton; 
transcription factor activity; actin binding 
Muscle contraction; regulation of transcription from RNA polymerase II promoter; cell motion; 
mesoderm development; cellular component morphogenesis; heart development; muscle organ 
development 
Cytoplasm; cytoskeleton 
Lipoma-preferred partner 82   DOWN 
Structural constituent of cytoskeleton; protein 
binding; kinase regulator activity 
Mitosis; cell motion; mitosis; signal transduction; mesoderm development; cellular component 
morphogenesis; muscle organ development 
Nucleus; cytoplasm; cell 
membrane 
LIM and SH3 domain protein 1 102   DOWN 
Structural constituent of cytoskeleton; actin 
binding 
Muscle contraction Cytoplasm; cytoskeleton 
Ezrin 264   DOWN Structural constituent of cytoskeleton Cellular component morphogenesis Cell projection; cytoskeleton 
Proteasome subunit alpha type-5 185 DOWN UP Peptidase activity Proteolysis Cytoplasm; nucleus 
14-3-3 protein theta 2 DOWN UP Signal transduction Cell cycle; signal transduction Cytoplasm 
60S acidic ribosomal protein P0 338 DOWN UP 
Structural constituent of ribosome; nucleic acid 
binding 
Translation Cytoplasm; nucleus 
Aspartyl aminopeptidase 132 UP   Proteolysis Aminopeptidase activity; metallopeptidase activity; zinc ion binding Cytoplasm 
Fascin 125 UP   
Structural constituent of cytoskeleton; actin 
binding 
Cell motion Cytoskeleton; cell projection 
Lamin A/C 79 UP   Structural constituent of cytoskeleton Cellular component morphogenesis Nucleus 
GANAB protein 330 UP   Glucosidase activity 
Polysaccharide metabolic process; monosaccharide metabolic process;  protein modification 
process 
Endoplasmic reticulum; golgi 
apparatus 
Tubulin-specific chaperone E 458 UP   
Post chaperonin tubulin folding pathway; protein 
folding; protein metabolic processes 
Cellular component morphogenesis Cytoskeleton 
Serine hydroxymethyltransferase 419 UP   Methyltransferase activity 
Nucleobase, nucleoside, nucleotide and nucleic acid metabolic process; cellular amino acid 
metabolic process 
Mitochondrion 
Annexin A11 227 UP   
Calcium ion binding; calcium-dependent 
phospholipid binding 
Synaptic vesicle exocytosis; intracellular protein transport;calcium-mediated signaling; fatty acid 
metabolic process; cell motion 
Cytoplasm; nucleus 
Moesin 318 UP UP Structural constituent of cytoskeleton Cellular component morphogenesis 
Cell membrane; cytoplasm; cell 
projection 
Eukaryotic translation initiation 
factor 2 subunit 1 
573 UP UP 
Translation factor activity, nucleic acid binding; 
translation initiation factor activity 
Translation Cytoplasm; nucleus 
L-caldesmon 110 UP UP 
Structural constituent of cytoskeleton; actin 
binding 
Mitosis; cellular component morphogenesis Cytoskeleton 
Osteoclast-stimulating factor 1 40 UP UP Signal transduction SH3 domain binding Cytoplasm 
T-complex protein 1 subunit theta 
138;133 UP UP Protein folding Protein folding; protein complex assembly Cytoplasm; cytoskeleton 
  
BPI3V Phosphoprotein P 
27;182;92;44;47;
401;819;255;235 
UP UP 
Viral genome replication; transcription DNA -
dependent 
RNA-binding; RNA-directed RNA polymerase activity NA 
Protein disulfide-isomerase A3 333;25 UP UP Protein disulfide isomerase activity Protein modification process Endoplasmic Reticulum 
Annexin 16   UP 
Calcium ion binding; calcium-dependent 
phospholipid binding 
Synaptic vesicle exocytosis; intracellular protein transport;exocytosis; calcium-mediated signaling; 
fatty acid metabolic process; cell motion 
Cytoplasm; nucleus 
Non-muscle myosin heavy chain 48   UP 
Motor activity;structural constituent of 
cytoskeleton;protein binding;small GTPase 
regulator activity 
Muscle contraction; sensory perception; intracellular protein transport; vesicle-mediated transport; 
cytokinesis; cell motion; mitosis; intracellular signaling cascade; cellular component 
morphogenesis; mesoderm development; muscle organ development 
Cytoplasm; cell membrane 
Nucleophosmin 57   UP 
Intacellular protein transport; nucleasome and 
ribosome assembly; viral reproduction 
rRNA metabolic process Nucleus; cytoskeleton 
6-phosphogluconolactonase 62   UP Hydrolase activity Pentose-phosphate shunt Cytoplasm 
14-3-3 protein beta/alpha 111   UP 
Protein binding; innate immune response; 
apoptotic process; activation of MAPKK activity 
Cell cycle; signal transduction; protein binding Cytoplasm 
Cystathionine gamma-lyase 134   UP Lyase activity Cellular amino acid metabolic process Cytoplasm 
Phosphoserine phosphatase 158   UP Phosphatase activity Cellular amino acid biosynthetic process Cytoplasm 
Heat shock 70 kDa protein 5;166 
  
UP 
Immune system process; protein folding; protein 
complex assembly; response to stress; protein 
complex biogenesis 
Hsp70 family chaperone Cytoplasm 
Proteasome subunit beta type 272   UP Proteolysis Peptidase activity Cytoplasm 
Calponin-3 357   UP Muscle contraction Structural constituent of cytoekeleton; actin binding Cytoskeleton 
Isocitrate dehydrogenase [NAD] 
subunit alpha 
481 
  
UP 
Generation of precursor metabolites and 
energy; carbohydrate metabolic process; 
tricarboxylic acid cycle 
Oxidoreductase activity Mitochondria 
Eukaryotic translation initiation 
factor 6 
532 
  
UP 
Translation; regulation of translation Translation initiation factor activity 
Cytoplasm 
